Hôpital Pierre Wertheimer

Lyon 69394

0 studies enrolling now · 2 studies all time

What they study most

Grade 2 Glioma, IDH1-mutant Glioma, IDH2-mutant Glioma, Recurrent Glioma, Residual Glioma

Studies at this site

• Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma — Running, not enrolling
• Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) — Running, not enrolling